Browse by author
Lookup NU author(s): Dr Paul Mackin,
Dr Peter GallagherORCiD
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The relationship between antipsychotic use and cardiovascular morbidity and mortality is controversial. There is a lack of long-term prospective studies investigating changes in cardiometabolic risk in patients treated with antipsychotic drugs. We report data from a 4-year prospective study. Patients (89) underwent detailed metabolic and cardiovascular risk assessment at 4-years which included anthropometric assessment, blood pressure, lipid profile, and an oral glucose tolerance test. We used the homeostatic model assessment to determine insulin resistance, and calculated 10-year cardiovascular risk scores. Mean age of subjects was 44.7 (+/- 11.5) years, and 52% were male. The prevalence of type 2 diabetes was 8%, and 38.4% fulfilled diagnostic criteria for the metabolic syndrome. With the exception of increased central adiposity over the 4-year follow-up period (p < 0.001), other cardiometabolic parameters were generally unchanged. There was a high prevalence of dyslipidaemia, but only 16.9% were prescribed lipid-lowering treatment. Commencing lipid-lowering therapy was associated with a reduction in cardiovascular risk score (OR 7.9, 95% CI = 1.3 to 48.7; p = 0.02). Patients established on longer-term antipsychotic treatment show less dramatic metabolic changes than those occurring in the early stages of treatment, but have a high burden of cardiovascular risk. Lipid-lowering therapy is associated with a significant reduction in cardiovascular risk. (C) 2010 Elsevier Masson SAS. All rights reserved.
Author(s): Mackin P, Waton T, Watkinson HM, Gallagher P
Publication type: Article
Publication status: Published
Journal: European Psychiatry
Print publication date: 30/10/2010
ISSN (print): 0924-9338
ISSN (electronic): 1778-3585
Publisher: Elsevier Masson
PubMed id: 21036552
Altmetrics provided by Altmetric